BUB1 and breast carcinoma: In vitro investigations into adenocarcinoma of the lung and breast cancer support the notion that BAY 1816032, which was previously thought to be a newly discovered inhibitor of BUB1 catalytic activity, may have therapeutic potential for the treatment of OS.